Welcome to our dedicated page for Aurinia Pharmace SEC filings (Ticker: AUPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial breakthroughs—or setbacks—can swing Aurinia Pharmaceuticals (AUPH) shares dramatically. Digging through dense risk factors, milestone payment tables, and drug safety sections in each filing is tough, especially when LUPKYNIS revenue guidance and AUR200 development costs are buried deep in footnotes. Investors often ask, “Where do I find the Aurinia Pharmaceuticals quarterly earnings report 10-Q filing?” or “How do I track Aurinia Pharmaceuticals insider trading Form 4 transactions?”
Stock Titan solves that problem. Our platform ingests every document the moment it hits EDGAR and provides Aurinia Pharmaceuticals SEC filings explained simply through AI-generated briefs that spotlight trial timelines, cash runway, and regulatory milestones. Whether you need the Aurinia Pharmaceuticals annual report 10-K simplified for long-term outlook, an Aurinia Pharmaceuticals 8-K material events explained alert after an FDA update, or Aurinia Pharmaceuticals Form 4 insider transactions real-time, the insight arrives in minutes. Understanding Aurinia Pharmaceuticals SEC documents with AI is now straightforward.
Use this page to:
- Receive instant alerts when an Aurinia Pharmaceuticals proxy statement executive compensation is posted.
- Compare trends with our Aurinia Pharmaceuticals earnings report filing analysis tools.
- Monitor Aurinia Pharmaceuticals executive stock transactions Form 4 ahead of key catalyst dates.
Every exhibit, footnote, and amendment is archived, cross-linked, and searchable. From shelf registrations to clinical-trial updates, you get comprehensive coverage, real-time updates, and AI-powered summaries that turn complex biotech disclosures into actionable knowledge.
Society Pass Incorporated (Nasdaq: SOPA) has filed a Form 8-K dated 30 June 2025 to furnish unaudited condensed and pro-forma consolidated balance sheets. Management estimates stockholders’ equity at US$2,584,706 as of 30 June 2025, comfortably clearing the Nasdaq Capital Market’s US$2.5 million minimum equity requirement under Listing Rule 5550(b)(1).
The filing includes Exhibit 99.1, which presents (i) unaudited condensed consolidated balance sheets as of 31 May 2025 and (ii) unaudited pro-forma consolidated balance sheets as of 30 June 2025. Exhibit 104 provides the Cover Page Inline XBRL data. No other material transactions, earnings data, or operational updates are disclosed.
By confirming compliance with the equity threshold, the company mitigates an immediate delisting risk and preserves its Nasdaq listing status. However, the buffer above the requirement is relatively narrow (≈ US$84 thousand), indicating that equity levels will need ongoing monitoring.
FAQ
What is the current stock price of Aurinia Pharmace (AUPH)?
What is the market cap of Aurinia Pharmace (AUPH)?
What is the primary focus of Aurinia Pharmaceuticals?
How does Aurinia Pharmaceuticals generate its revenue?
Which therapeutic areas are the main targets for Aurinia's research?
What sets Aurinia’s drug development strategy apart?
How does the company handle regulatory compliance?
What role do clinical trials play in Aurinia's business model?
How does Aurinia position itself in the competitive biopharmaceutical landscape?
What challenges does the company face in its operations?
